Clinical use of albumin in hepatology

Blood Transfusion

Volumn 7, Issue 4, 2009, Pages 268-277

  Garcovich, Matteo ^a   Zocco, Maria Assunta ^a   Gasbarrini, Antonio ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFOTAXIME; CEPHALOSPORIN; FUROSEMIDE; MIDODRINE; NORADRENALIN; OCTREOTIDE; OXIDIZING AGENT; SPIRONOLACTONE; TERLIPRESSIN;

ANTIOXIDANT ACTIVITY; ASCITES; BACTERIAL PERITONITIS; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG USE; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; ONCOTIC PRESSURE; PARACENTESIS; PATHOGENESIS; REVIEW;

FIBROSIS; GASTROENTEROLOGY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; SERUM ALBUMIN;

EID: 73449142512     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0080-08     Document Type: Review

References (80)

1. Janeway CA, Gibson ST, Woodruff LM, et al. Chemical, clinical and immunological studies on the products of human plasma fractionation: concentrated human serum albumin. J Clin Invest 1944; 23: 465-91.
2. Peters T. All About Albumin: Biochemistry, Genetics, and Medical Applications. San Diego, CA: Academic Press, 1996.
3. Redman CM. Biosynthesis of serum proteins and ferritin by free and attached ribosomes of rat liver. Biochem Biophys Res Commun 1968; 33: 55-60.
4. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth 2000; 85: 599-610.
5. Beeken WL, Volwiler W, Goldsworthy PD, et al. Studies of I-131-albumin catabolism and distribution in normal young male adults. J Clin Invest 1962; 41: 1312-33.
6. Nguyen MK, Kurtz I. Quantitative interrelationship between Gibbs-Donnan equilibrium, osmolality of body fluid compartments, and plasma water sodium concentrations. J Appl Physiol 2006; 100: 1293-300.
7. Kouoh F, Gressier B, Luyckx M, et al. Antioxidant properties of albumin: effect on oxidative metabolism of human neutrophil granulocytes. Farmaco 1999; 54: 695-9.
8. Wratten ML, Sereni L, Tetta C. Oxidation of albumin is enhanced in the presence of uremic toxins. Ren Fail 2001; 23: 563-71 .
9. Ogasawara Y, Isoda S, Tanabe S. Antioxidant effects of albumin-bound sulfur in lipid peroxidation of rat liver microsomes. Biol Pharm Bull 1999; 22: 441-5.
10. Quinlan GJ, Mumby S, Martin GS, et al. Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med 2004; 32: 755-9.
11. Soejima A, Matsuzawa N, Miyake N, et al. Hypoalbuminemia accelerates erythrocyte membrane lipid peroxidation in chronic hemodialysis patients. Clin Nephrol 1999; 51: 92-7.
12. Rubbo H, Parthasarathy S, Barnes S, et al. Nitric oxide inhibition of lipoxygenase-dependent liposome and low-density lipoprotein oxidation: termination of radical chain propagation reactions and formation of nitrogen-containing oxidized lipid derivatives. Arch Biochem Biophys 1995; 324: 15-25.
13. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci U S A 1987; 84: 5918-22.
14. Neuzil J, Stocker R. Bilirubin attenuates radical-mediated damage to serum albumin. FEBS Lett 1993; 331: 281-4.
15. Wardell M, Wang Z, Ho JX, et al. The atomic structure of human methemalbumin at 1.9 A. Biochem Biophys Res Commun 2002; 291: 813-9.
16. Vincent SH, Grady RW, Shaklai N, et al. The influence of heme-binding proteins in heme-catalyzed oxidations. Arch Biochem Biophys 1988; 265: 539-50.
17. Gutteridge JM, Smith A. Antioxidant protection by haemopexin of haem-stimulated lipid peroxidation. Biochem J 1988; 256: 861-5.
18. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32: 1025-33.
19. Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. Am J Med 1958; 24: 358-67.
20. Groszmann RJ. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In: Bosch, J, Groszmann, RJ, eds. Portal Hypertension. Pathophysiology and Treatment. Oxford, UK: Blackwell 1994: 17-26.
21. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
22. Starling JH. Contribution to the physiology of lymph secretion. J Physiol (Lond) 1893; 14: 131-53.
23. Wilkinson P, Sherlock S. The effect of repeated albumin infusions in patients with cirrhosis. Lancet 1962; 2(7266):1125-9.
24. Lieberman FL, Denison EK, Reynolds TB. The relationship of plasma volume, portal hypertension, ascites and renal sodium and water retention in cirrhosis: the 'overflow' theory of ascites formation. Ann NY Acad Sci 1970; 170: 202-6.
25. Fernàndez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97: 1304-12.
26. Saadeh S, Davis GL. Management of ascites in patients with end-stage liver disease. Rev Gastroenterol Disord 2004; 4: 175-85.
27. Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-54.
28. Heneghan MA, Harrison PM. Pathogenesis of ascites in cirrhosis and portal hypertension. Med Sci Monit 2000; 6: 807-16.
29. Maroto A, Ginès A, Salò J, et al. Diagnosis of functional renal failure of cirrhosis by Doppler sonography: prognostic value of resistive index. Hepatology 1994; 20: 839-44.
30. Maroto A, Ginès P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993; 17: 788-93.
31. Guevara M, Bru C, Ginès P, et al. Increased cerebral vascular resistance in cirrhotic patients with ascites. Hepatology 1998; 28: 39-44.
32. Hori N, Wiest R, Groszman RJ. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. Hepatology 1998; 28: 1467-73.
33. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-66.
34. Quintero E, Ginès P, Arroyo V, et al. Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites. Lancet 1985; 1: 611-2.
35. Ginès P, Titò L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-502.
36. Ruiz-del-Arbol L, Monescillo A, Jiménez W, et al. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-86.
37. Sola-Vera J, Miñana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003; 37: 1147-53.
38. García-Compean D, Blanc P, Larrey D, et al. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol 2002; 1: 29-35.
39. Ginès A, Fernández-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-110.
40. Sheer TA, Runyon BA. Spontaneous bacterial peritonitis. Dig Dis 2005; 23: 39-46.
41. Scarpellini E, Merra G, Gasbarrini A et al. 51CR-EDTA permeability test in ascetic cirrhotic patients with and without history of spontaneous bacterial peritonitis. Gut 2008, 57: A390.
42. Guarner C, Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol 2005; 17: 27-31.
43. Hoefs JC, Canawati HN, Sapico FL, et al. Spontaneous bacterial peritonitis. Hepatology 1982; 2: 399-407.
44. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 6: 403-9.
45. Fernández J, Monteagudo J, Bargallo X, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42: 627-34.
46. Patch D, Burroughs A. Intravenous albumin in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 23: 1773-4.
47. Runyon BA. Albumin infusion for spontaneous bacterial peritonitis. Lancet 1999; 354: 1838-9.
48. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-8.
49. Henriksen JH, Bendtsen F, Sørensen TI, et al. Reduced central blood volume in cirrhosis. Gastroenterology 1989; 97:1506-13.
50. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005, 42: 439-47.
51. Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis. Am J Med 1970; 49: 175-85.
52. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923-30.
53. Guevara M, Ginès P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41.
54. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002; 36: 374-80.
55. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64.
56. Guelberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 870-5.
57. Uriz J, Ginès P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-8.
58. Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective nonrandomized study. Hepatology 2002; 36: 941-8.
59. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006; 43: 385-94.
60. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-7.
61. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64.
62. Maor Y. The use of albumin in patients with decompensated cirrhosis: the case in favor. Isr Med Assoc J 2005; 7: 115-8.
63. Cardenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterol 2005; 100: 460-7.
64. Gentilini P, Bernardi M, Bolondi L, et al. The rational use of albumin in patients with cirrhosis and ascites. A Delphi study for the attainment of a consensus on prescribing standards. Dig Liver Dis 2004; 36: 539-46.
65. Schindler C, Ramadori G. Albumin substitution improves urinary sodium excretion and diuresis in patients with liver cirrhosis and refractory ascites. J Hepatol 1999; 31:1132.
66. Trotter J, Pieramici E, Everson GT. Chronic albumin infusions to achieve diuresis in patients with ascites who are not candidates for transjugular intrahepatic portosystemic shunt (TIPS). Dig Dis Sci 2005 ; 50: 1356-60.
67. Gentilini P, Casini-Raggi V, DiFiore GD, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999; 30: 639-45.
68. Romanelli RG, La Villa G, Barletta G, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: un unblinded randomized trial. World J Gastroenterol 2006; 12: 1403-7.
69. Tandon P, Tsuyuki RT, Mitchell L, et al. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int 2009; 29: 169-74.
70. Trey C, Davidson CS. The management of fulminant hepatic failure. Prog Liver Dis 1970; 3: 282-98.
71. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002; 22 (Suppl 2): 5-13.
72. Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am J Gastroenterol 2005; 100: 468-75.
73. Sen S, Jalan R, Williams R. Liver failure: basis of benefit of therapy with the molecular adsorbents recirculating system. Int J Biochem Cell Biol 2003; 35: 1306-11.
74. Stange J, Ramlow W, Mitzner S, et al. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 1993; 17: 809-13.
75. Pares A, Cisneros L, Salmeron JM, et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 1105-10.
76. Doria C, Mandala L, Smith J, et al. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transplant 2003; 9: 437-43.
77. Sen S, Felldin M, Steiner C, et al. Albumin dialysis and molecular adsorbents recirculating system (MARS) for acute Wilson's disease. Liver Transpl 2002; 8: 962-7.
78. Stange J, Mitzner SR, Risler T, et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999; 23: 319-30.
79. Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver 2002; 22(Suppl 2): 20-5.
80. Mitzner S, Loock J, Peszynski P, et al. Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARS: a review of clinical, biochemical, and electrophysiological data. Metab Brain Dis 2002; 17: 463-75.